image
Dr. Reddy's Laboratories Limited RDY
Healthcare - Drug Manufacturers - Specialty & Generic - NYSE - IN
Watchlist
$ 14.17
-0.492 %
$ 12.2 B
Market Cap
18.17
P/E
1. INTRINSIC VALUE

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), Proprietary Products, and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations. This segment also engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements.[ Read More ]

The intrinsic value of one RDY stock under the base case scenario is HIDDEN Compared to the current market price of 14.2 USD, Dr. Reddy's Laboratories Limited is HIDDEN

RDY Intrinsic Value
HIDDEN
SHOW
2. FUNDAMENTAL ANALYSIS

Price Chart RDY

image
FINANCIALS
279 B REVENUE
13.54%
Growth Rates
1Year 13.54%
3Years 13.74%
5Years 12.66%
7Years 10.27%
10Years 7.76%
67.7 B OPERATING INCOME
-29.66%
Growth Rates
1Year -29.66%
3Years 23.38%
5Years 26.52%
7Years 25.91%
10Years 10.03%
55.7 B NET INCOME
-7.94%
Growth Rates
1Year -7.94%
3Years 42.73%
5Years 24.26%
7Years 24.46%
10Years 9.98%
45.4 B OPERATING CASH FLOW
-22.83%
Growth Rates
1Year -22.83%
3Years 8.36%
5Years 9.62%
7Years 11.27%
10Years 8.85%
-40.3 B INVESTING CASH FLOW
2.63%
Growth Rates
1Year 2.63%
3Years -21.14%
5Years -39.13%
7Years -11.78%
10Years -9.26%
-3.76 B FINANCING CASH FLOW
85.99%
Growth Rates
1Year 85.99%
3Years -132.87%
5Years 29.32%
7Years -0.27%
10Years -33.02%
80.2 B REVENUE
4.48%
Growth Rates
1Year 13.54%
3Years 13.74%
5Years 12.66%
7Years 10.27%
10Years 7.76%
17.6 B OPERATING INCOME
-2.09%
Growth Rates
1Year -29.66%
3Years 23.38%
5Years 26.52%
7Years 25.91%
10Years 10.03%
13.4 B NET INCOME
-3.63%
Growth Rates
1Year -7.94%
3Years 42.73%
5Years 24.26%
7Years 24.46%
10Years 9.98%
9.32 B OPERATING CASH FLOW
9.65%
Growth Rates
1Year -22.83%
3Years 8.36%
5Years 9.62%
7Years 11.27%
10Years 8.85%
-19.1 B INVESTING CASH FLOW
5.81%
Growth Rates
1Year 2.63%
3Years -21.14%
5Years -39.13%
7Years -11.78%
10Years -9.26%
16.2 B FINANCING CASH FLOW
69.27%
Growth Rates
1Year 85.99%
3Years -132.87%
5Years 29.32%
7Years -0.27%
10Years -33.02%
Balance Sheet Decomposition Dr. Reddy's Laboratories Limited
image
Current Assets 248 B
Cash & Short-Term Investments 81.5 B
Receivables 80.3 B
Other Current Assets 86.3 B
Non-Current Assets 139 B
Long-Term Investments 5.26 B
PP&E 76.9 B
Other Non-Current Assets 57.3 B
Current Liabilities 96 B
Accounts Payable 21.5 B
Short-Term Debt 14 B
Other Current Liabilities 60.5 B
Non-Current Liabilities 10.9 B
Long-Term Debt 5.99 B
Other Non-Current Liabilities 4.94 B
EFFICIENCY
Earnings Waterfall Dr. Reddy's Laboratories Limited
image
Revenue 279 B
Cost Of Revenue 116 B
Gross Profit 164 B
Operating Expenses 95.9 B
Operating Income 67.7 B
Other Expenses 12 B
Net Income 55.7 B
RATIOS
58.61% GROSS MARGIN
58.61%
Averages
1Year 58.61%
3Years 64.75%
5Years 60.49%
7Years 58.63%
10Years 58.33%
24.26% OPERATING MARGIN
24.26%
Averages
1Year 24.26%
3Years 27.49%
5Years 24.54%
7Years 20.67%
10Years 19.11%
19.95% NET MARGIN
19.95%
Averages
1Year 19.95%
3Years 16.42%
5Years 13.90%
7Years 12.66%
10Years 12.51%
19.85% ROE
19.85%
Averages
1Year 19.85%
3Years 17.19%
5Years 14.80%
7Years 13.59%
10Years 14.04%
14.37% ROA
14.37%
Averages
1Year 14.37%
3Years 12.09%
5Years 10.23%
7Years 9.12%
10Years 9.03%
17.66% ROIC
17.66%
Averages
1Year 17.66%
3Years 20.17%
5Years 19.09%
7Years 15.70%
10Years 14.33%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Dr. Reddy's Laboratories Limited
image
Net Income 55.7 B
Depreciation & Amortization 14.8 B
Capital Expenditures -27.4 B
Stock-Based Compensation 407 M
Change in Working Capital -20.2 B
Others -15.2 B
Free Cash Flow 18 B
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Dr. Reddy's Laboratories Limited
image
RDY has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
0.00% DIVIDEND YIELD
0.479 USD DIVIDEND PER SHARE
5. COMPETITION

Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States.

image
63.1 USD
PCRX
Undervalued 280.31%

Phibro Animal Health Corporation develops, manufactures, and supplies a range of animal health and mineral nutrition products for livestock primarily in the United States.

image
-0.753 USD
PAHC
Overvalued 103.08%

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ER for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment.

image
57.1 USD
COLL
Undervalued 93.04%

ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada.

image
-55.4 USD
ANIP
Overvalued 197.92%

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally.

image
20.2 USD
ALKS
Overvalued 28.20%

Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States.

image
-1.61 USD
ITCI
Overvalued 101.93%

Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States.

image
43.8 USD
EGRX
Undervalued 4771.98%

Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally.

image
216 USD
PBH
Undervalued 162.17%

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as diabetes and complications of diabetes, fibrosis, infectious diseases, CNS diseases, oncology, pain and inflammation, immunology, rare diseases, respiratory diseases, and women's health.

image
9.43 USD
EVO
Undervalued 73.30%

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States.

image
91.3 USD
SUPN
Undervalued 156.69%
6. Ownership
Insider Ownership Dr. Reddy's Laboratories Limited
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
Date Value Insider Amount Avg Price
7. News
Dr. Reddy's Q2 Earnings Miss Estimates, Global Generics Revenues Grow RDY misses on earnings but beats on revenues in the fiscal second quarter. The bottom line suffers due to a one-time acquisition cost and impairment charge on non-current assets. zacks.com - 1 week ago
Dr. Reddy's Laboratories Limited (RDY) Q2 2025 Earnings Call Transcript Dr. Reddy's Laboratories Limited (NYSE:RDY ) Q2 2025 Earnings Conference Call November 5, 2024 9:00 AM ET Company Participants Richa Periwal - Head of Investor Relations MV Narasimham - Chief Financial Officer Erez Israeli - Chief Executive Officer Conference Call Participants Kunal Dhamesha - Macquarie Neha Manpuria - Bank of America Amey Chalke - JM Financial Mikaela Franceschina - Barclays Harith Ahmad - Avendus Spark Damayanti Kerai - HSBC Bino Pathiparampil - Elara Capital Surya Patra - PhillipCapital Tarang Agarwal - Old Bridge Kunal Randeria - Axis Capital Anubhav Agarwal - UBS Vishal Manchanda - Systematix Operator Ladies and gentlemen, good day, and welcome to the Quarter Two FY 2025 Earnings Conference Call of Dr. Reddy's Laboratories Limited. As a reminder, all participants' lines will be in the listen-only mode and there will be an opportunity for you to ask questions after the presentation concludes. seekingalpha.com - 1 week ago
Dr. Reddy's Q2 & H1FY25 Financial Results HYDERABAD, India--(BUSINESS WIRE)---- $RDY #DrReddys--Dr. Reddy's Laboratories Ltd. today announced its consolidated financial results for the quarter and half year ended September 30, 2024. businesswire.com - 1 week ago
Dr. Reddy's Named by Science Magazine in Top 20 Global Pharma Employers List for Third Consecutive Year HYDERABAD, India--(BUSINESS WIRE)---- $RDY #AmericanAssociationfortheAdvancementofScience--Dr. Reddy's has been ranked among the top employers according to the 2024 Top Biotech and Pharma Employers Survey conducted by Science. businesswire.com - 3 weeks ago
Dr. Reddy's Launches Comprehensive Menopause Support Program and Training for Employees During Menopause Awareness Month PRINCETON, N.J.--(BUSINESS WIRE)---- $RDY #DRREDDY--Dr. Reddy's launches comprehensive menopause support program and training for employees during menopause awareness month. businesswire.com - 1 month ago
Aurigene Oncology Limited Announces Promising Results of Phase 1 Study for India's First Trial for Novel Autologous CAR-T Cell Therapy for Multiple Myeloma BENGALURU, India & HYDERABAD, India--(BUSINESS WIRE)-- #AurigeneOncology--Aurigene Oncology announces promising results of Phase 1 study for India's first trial for novel autologous CAR-T cell therapy for multiple myeloma. businesswire.com - 1 month ago
Dr. Reddy's signs voluntary licensing agreement with Gilead Sciences to manufacture and commercialise Lenacapavir in India and other countries HYDERABAD, India--(BUSINESS WIRE)---- $RDY #DRREDDY--Dr. Reddy's signs voluntary licensing agreement with Gilead Sciences to manufacture and commercialise Lenacapavir in India and other countries. businesswire.com - 1 month ago
Here's Why Doctor Reddy's (RDY) is a Strong Value Stock The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage. zacks.com - 1 month ago
Dr. Reddy's (RDY), Kainomyx Sign Potential Deal for Malaria Drug Dr. Reddy's (RDY) is gearing up to potentially collaborate with Kainomyx to jointly develop an affordable anti-malarial drug. zacks.com - 2 months ago
Dr. Reddy's Laboratories: Economic Factors Square Off To Reiterate Buy Dr. Reddy's Laboratories stock has risen 29% since my last publication, with additional tailwinds from legislative changes and strong business momentum. The company's enduring competitive advantage as a generics pharmaceutical manufacturer produces abnormally high and persistent returns on capital. Quarterly insights show growth in U.S. generics, Europe, and India markets, with high-quality economic characteristics supporting $107/share intrinsic value. seekingalpha.com - 3 months ago
Dr. Reddy's (RDY) Q1 Earnings Miss Estimates, Revenues Beat Dr. Reddy's (RDY) reports mixed first-quarter fiscal 2025 results, wherein earnings lag estimates, but revenues beat the same, driven by growth in global generics sales in North America and India. zacks.com - 3 months ago
Dr. Reddy's Q1FY25 Financial Results HYDERABAD, India--(BUSINESS WIRE)---- $RDY #DRREDDY--Dr. Reddy's Laboratories Ltd. today announced its consolidated financial results for the quarter ended June 30, 2024. businesswire.com - 3 months ago
8. Profile Summary

Dr. Reddy's Laboratories Limited RDY

image
COUNTRY IN
INDUSTRY Drug Manufacturers - Specialty & Generic
MARKET CAP $ 12.2 B
Dividend Yield 0.00%
Description Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), Proprietary Products, and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations. This segment also engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. Its Proprietary Products segment focuses on the research and development of differentiated formulations. The Others segment engages in developing therapies in the fields of oncology and inflammation. The therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. The company has a collaboration, license, and option agreement with Curis, Inc. to discover, develop, and commercialize small molecule antagonists for immuno-oncology and precision oncology targets. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.
Contact 8-2-337, Road No. 3, Hyderabad, 500034 https://www.drreddys.com
IPO Date April 11, 2001
Employees 27048
Officers Mr. Mannam Venkatanarasimham Chief Financial Officer & Member of the Management Council Mr. Deepak Sapra M.B.A. Chief Executive Officer of API & Services & Member of Management Council Ms. Archana Bhaskar B.Sc., M.B.A. EVice President, Head of Corporate Communications, Chief Human Resources Officer & Member of Management Council Mr. Patrick Aghanian B.A., M.B.A. Chief Executive Officer of European Generics & Member of Management Council Mr. Kallam Satish Reddy B.Tech., M.S. Chairman of the Board & Member of the Management Council Mr. Krishna K. Venkatesh B.Pharma M.S. Global Head of Quality and Pharmacovigilance & Member of the Management Council Mr. Venkata Ramana Motupalli M.B.A. Chief Executive Officer of Branded Markets - India & Emerging Countries and Member of Management Council Mr. Sanjay Sharma B.Tech. Executive Vice President, Global Head of Global Manufacturing & Member of Management Council Mr. Gunupati Venkateswara Prasad B.E. Co-Chairman, MD & Member of Management Council Mr. Erez Israeli M.B.A. Chief Executive Officer & Member of the Management Council